S&P 500
7,517.60
-0.02%
Dow Jones
52,417.00
-0.20%
Nasdaq 100
29,288.00
+0.10%
Russell 2000
2,951.36
0.00%
FTSE 100
10,441.80
-0.66%
Nikkei 225
67,229.70
+0.25%

Investing

Merck Will Seek FDA Approval for Insomnia Drug (MRK)

Photo of Paul Ausick
By Paul Ausick Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Drug giant Merck & Co. (NYSE: MRK) plans to file this year with the US FDA for approval of the company’s newest sleep aid drug, suvorexant. The drug has completed late-stage trials with positive results. It is one of five drugs that Merck hopes will gain FDA approval in 2012 and 2013.

The company lost patent protection on its Singulair asthma drug in August, and Merck needs new drugs to fill the gap. The Wall Street Journal cites an estimate of $500 million in sales for the new drug once it is widely available.

Merck said the drug does not pose any serious safety threat and that patients who discontinued use of the drug due to its side effects did so in the same numbers as patients receiving placebo.

Contact [email protected] for any questions or corrections.

Disclaimer: Energy Exploration Technologies, Inc. ("EnergyX") has engaged 24/7 Wall St to publish this communication in connection with EnergyX's ongoing Regulation A offering. 24/7 Wall St has been paid in cash and may receive additional compensation. 24/7 Wall St and/or its affiliates do not currently hold securities of EnergyX.

This compensation and any current or future ownership interest could create a conflict of interest. Please consider this disclosure alongside EnergyX's offering materials. EnergyX's Regulation A offering has been qualified by the SEC. Offers and sales may be made only by means of the qualified offering circular. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at invest.energyx.com/.

Comparisons to other companies are for informational purposes only and should not imply similar results. Past performance is not indicative of future results. Market shortfall are forward‑looking estimates and are subject to substantial uncertainty. Investments in private placements, and start-up investments in particular, are long-term, illiquid, speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups

Follow 24/7 Wall St. on Google
Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Merck Wins Yet Again With New Keytruda Approval
Chris Lange |

Merck Wins Yet Again With New Keytruda Approval

Merck shares were up slightly on Wednesday after the pharma giant gave another key update for its KEYTRUDA line. The…

Douglas A. McIntyre |

GTX Soaring On Merck Collaboration (GTXI, MRK)

GTx, Inc. (NASDAQ: GTXI) is seeing shares trade sharply higher on a collaboration pact with Merck (NYSE: MRK).  The biotech…

High Hopes and Expectations for Merck’s First Investor Day in Years
Jon C. Ogg |

High Hopes and Expectations for Merck’s First Investor Day in Years

Merck is set to host its Investor Day on June 20. Investors will have a high bar of expectations because…

Jon C. Ogg |

What This Skin Cancer Drug Approval Really Means to Merck

Merck & Co. has received approval from the FDA to bring its new drug Keytruda to market.

Douglas A. McIntyre |

Lipitor OTC: What Next? (PFE, MRK, AZN, SNY, BMY, LLY, JNJ, AMGN)

Once patent protection expires on a prescription drug, the drug’s maker can take a serious beating in revenue and profitability.…

3 Big Pharma Stocks With Credible Threats to Their Blockbusters
Trey Thoelcke |

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

A pharmaceutical company could face a threat to one of its products for a number of reasons, ranging from an…

Merck Wins Another FDA Approval For Keytruda
Chris Lange |

Merck Wins Another FDA Approval For Keytruda

Merck & Co., Inc. (NYSE: MRK) shares took a small step back on Thursday after the company announced a key…

Merck’s Accelerated Keytruda Lung Cancer Approval Creates 3 Moves
Jon C. Ogg |

Merck’s Accelerated Keytruda Lung Cancer Approval Creates 3 Moves

It is no secret that pharma and biotech shares have had to deal with at least some headwinds over the…

Chris Lange |

5 Big FDA Decisions Expected in October

24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of October and…

Top Gaining Stocks

FactSet Research Systems
FDS • Vol: 929,614
Gartner
IT • Vol: 1,375,344
Intuit
INTU • Vol: 6,564,709
Valero Energy
VLO • Vol: 2,870,552
Paycom Software
PAYC • Vol: 620,867

Top Losing Stocks

Coterra Energy
CTRA • Vol: 73,319,495
Oracle
ORCL • Vol: 56,688,573
Intel
INTC • Vol: 100,754,655
Lam Research
LRCX • Vol: 9,770,514
ON Semiconductor
ON • Vol: 9,568,853